ABD-3, the confluence of powerful antibacterial modalities: ABDs delivering and expressing ls s, the gene encoding lysostaphin
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00235-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Geeta Ram und 5 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Lysostaphin. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
In response to the antimicrobial resistance crisis, we have developed a powerful and versatile therapeutic platform, the Antibacterial Drone (ABD) system. The ABD consists of a highly mobile staphylococcal pathogenicity island re-purposed to deliver genes encoding antibacterial proteins. The chromosomally located island is induced by a co-resident helper phage, packaged in phage-like particles, and released in very high numbers upon phage-induced lysis. ABD particles specifically adsorb to bacteria causing an infection and deliver their DNA to these bacteria, where the bactericidal cargo genes are expressed, kill the bacteria, and cure the infection. Here, we report a major advance of the system, incorporation of the gene encoding a secreted, bactericidal, species-specific lytic enzyme, lysostsphin. This ABD not only kills the bacterium that has been attacked by the ABD, but also any surrounding bacteria that are sensitive to the lytic enzyme which is released by secretion and by lysis of the doomed cell. So while the killing field is thus expanded, there are no civilian casualties (bacteria that are insensitive to the ABD and its cargo protein(s) are not inadvertently killed). Without amplifying the number of ABD particles (which are not re-packaged), the expression and release of the cargo gene’s product dramatically extend the effective reach of the ABD. A cargo gene that encodes a secreted bactericidal protein also enables the treatment of a mixed bacterial infection in which one of the infecting organisms is insensitive to the ABD delivery system but is sensitive to the ABD’s secreted cargo protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medicine and Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
- Cellinfinity Bio, New Haven, Connecticut, USA.
- Microscopy Core, Division of Advanced Research Technologies, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Geeta Ram, Richard P Novick
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Ram, G., Chiu, L., Dey, S., Ross, H. F., Cammer, M., & Novick, R. P. (2024). ABD-3, the confluence of powerful antibacterial modalities: ABDs delivering and expressing ls s, the gene encoding lysostaphin. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00235-24
Vancouver
Ram G, Chiu L, Dey S, Ross HF, Cammer M, Novick RP. ABD-3, the confluence of powerful antibacterial modalities: ABDs delivering and expressing ls s, the gene encoding lysostaphin. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00235-24
BibTeX
@article{Ram2024,
author = {Ram, Geeta and Chiu, LiTing and Dey, Somrita and Ross, Hope F and Cammer, Michael and Novick, Richard P},
title = {ABD-3, the confluence of powerful antibacterial modalities: ABDs delivering and expressing ls s, the gene encoding lysostaphin},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00235-24}
}
EUVIMED